Akero Therapeutics
Akero Therapeutics is a clinical-stage company dedicated to developing transformational treatments for serious metabolic diseases, with a focus on metabolic dysfunction-associated steatohepatitis (MASH). They leverage novel biology, including the natural hormone FGF21, to address high unmet medical needs through innovative therapies. Their mission is to restore whole-body metabolic balance and reverse fibrosis, aiming to improve patients' lives worldwide.
Industries
Nr. of Employees
small (1-50)
Akero Therapeutics
601 Gateway Boulevard, Suite 350, South San Francisco, CA 94080
Products
Efruxifermin (EFX)
An investigational drug designed to treat metabolic dysfunction-associated steatohepatitis (MASH) by mimicking the biological activity of fibroblast growth factor 21 (FGF21) to regulate multiple metabolic pathways and cellular processes.
Clinical Trials
Ongoing and completed clinical trials evaluating the safety and efficacy of EFX in patients with MASH, including the SYNCHRONY, SYMMETRY, HARMONY, and BALANCED studies.
Pipeline Development
Evaluation and development of potential treatments for MASH and other serious metabolic diseases to expand the therapeutic pipeline.
Manufacturing Partnerships
Collaborations with Boehringer-Ingelheim and Vetter Pharma to ensure high-quality active pharmaceutical ingredients (API) and drug products.
Efruxifermin (EFX)
An investigational drug designed to treat metabolic dysfunction-associated steatohepatitis (MASH) by mimicking the biological activity of fibroblast growth factor 21 (FGF21) to regulate multiple metabolic pathways and cellular processes.
Clinical Trials
Ongoing and completed clinical trials evaluating the safety and efficacy of EFX in patients with MASH, including the SYNCHRONY, SYMMETRY, HARMONY, and BALANCED studies.
Pipeline Development
Evaluation and development of potential treatments for MASH and other serious metabolic diseases to expand the therapeutic pipeline.
Manufacturing Partnerships
Collaborations with Boehringer-Ingelheim and Vetter Pharma to ensure high-quality active pharmaceutical ingredients (API) and drug products.
News & Updates
Reported topline results demonstrating statistically significant reversal of cirrhosis in patients with compensated cirrhosis (F4) following 96 weeks of treatment with EFX.
Reported topline week 96 data showing statistically significant histological improvements, demonstrating ≥1- and ≥2-stage fibrosis improvement without worsening of MASH at both 50mg and 28mg doses of EFX.
With gross proceeds of approximately $230M.
For the treatment of MASH.
Research article discussing the use of qFibrosis in early detection of fibrosis response in patients treated with EFX.
Study results showing the efficacy of EFX in improving fibrosis in cirrhotic patients.
Reported topline results demonstrating statistically significant reversal of cirrhosis in patients with compensated cirrhosis (F4) following 96 weeks of treatment with EFX.
Reported topline week 96 data showing statistically significant histological improvements, demonstrating ≥1- and ≥2-stage fibrosis improvement without worsening of MASH at both 50mg and 28mg doses of EFX.
With gross proceeds of approximately $230M.
For the treatment of MASH.
Research article discussing the use of qFibrosis in early detection of fibrosis response in patients treated with EFX.
Study results showing the efficacy of EFX in improving fibrosis in cirrhotic patients.